The unanticipated complexities of personalised medicine in the clinic
- At: 2014 FIP Congress in PSWC, Melbourne (Australia)
- Type: Presentation
- By: WARD, Robyn (UNSW, Prince of Wales Clinical School, Randwick nsw, Australia)
Molecular markers are used to select individuals with a differential benefit to specific therapies. In the case of high cost therapies such as anti-EGFR antibodies, a predictive biomarker represents an opportunity to limit therapy to the subgroup of patients most likely to benefit, thus improving cost-effectiveness of the drug. These and other.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.